A 67-year-old woman with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) is on an angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA). Which therapy further reduces heart failure hospitalization and mortality regardless of diabetes status?